Mersana Therapeutics (MRSN) Misses Q4 EPS by 28c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
March 8, 2019 6:00 AM ESTCompany Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019
Ended 2018 with $70 Million in Cash
Further Strengthened Balance Sheet with Gross Proceeds of $98 Million from Equity Financing; Expected to Fund the Company Through Important Clinical Milestones
CAMBRIDGE, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial... More
